MARCH 9, 2017 (SAN ANTONIO, TX) The San Antonio City Council today authorized the San Antonio Economic Development Corporation (SAEDC) to invest in locally based bioAffinity Technologies, a biotech company focused on the significant unmet need for non-invasive, early- stage cancer diagnostics and improved cancer treatments. The Economic Development Agreement with the SAEDC requires bioAffinity […]
AUGUST 25, 2016 As published in the San Antonio Business Journal By W. Scott Bailey City Council authorized the San Antonio Economic Development Corporation on Thursday to directly invest in bioAffinity Technologies. It’s another indication that City Hall is looking to strengthened its commitment to the community’s bioscience industry. The SAEDC has been […]
JULY 13, 2016 As published in the San Antonio Business Journal By W. Scott Bailey One of San Antonio’s more promising bioscience companies, bioAffinity Technologies Inc., has locked up a key deal, renewing its collaborative agreement with the University of Texas Health Science Center at San Antonio. The extension will allow the two organizations to […]
JULY 8, 2016 As published in the San Antonio Business Journal By W. Scott Bailey San Antonio’s bioAffinity Technologies Inc. has hired a senior executive with strong ties to the city’s bioscience industry to help lead its new subsidiary — OncoSelect Therapeutics LLC. William Bauta will join bioAffinity in September as senior vice […]
APRIL 9, 2016 As published in the San Antonio Business Journal By W. Scott Bailey San Antonio based bioAffinity Technologies is moving closer to commercializing its initial cancer diagnostics technology via a combination of new funding and strategic hires, according to President and CEO Maria Zannes. The privately-held, development-state biotech company has launched a Series […]
APRIL 6, 2016 As published in the San Antonio Express News By Peggy O’Hare, Staff Writer The problem with early lung cancer screening is the unnecessary worry for the 97 percent of patients flagged with suspicious results — that ultimately turn out to be inaccurate. San Antonio cancer diagnostics company bioAffinity Technologies Inc. thinks it […]